Staphylococcus (e.g., Staphylococcus Aureus, Etc.) Patents (Class 424/243.1)
-
Patent number: 7767211Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: GrantFiled: March 8, 2006Date of Patent: August 3, 2010Assignee: Absynth Biologics LimtedInventors: Simon J. Foster, Jorge Garcia-Lara
-
Publication number: 20100189748Abstract: A vaccine is disclosed that is protective against pathogenic bacterial species, typically staphylococcal species, and includes methods to prepare said vaccine and to culture pathogenic bacteria.Type: ApplicationFiled: July 23, 2007Publication date: July 29, 2010Inventors: Afshan Ahmad, Bruce Robert Gordon Skinner
-
Patent number: 7754225Abstract: A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species of Staphylococcus or various types of Staphylococcus epidermidis.Type: GrantFiled: July 20, 2006Date of Patent: July 13, 2010Assignee: Glaxosmithkline Biologicals S.A.Inventors: Ali Fattom, Jawad Sarwar, Zuzana Kossaczka, Kimberly L. Taylor, Sofiane Ennifar
-
Patent number: 7744906Abstract: The present invention concerns the use of a heat shock polypeptide and/or an encoding nucleic acid sequence in the manufacture of a medicament for use in the relief of pain. In particular the invention concerns the use of chaperonin. The invention further provides methods of relieving pain medicaments containing the heat shock polypeptides.Type: GrantFiled: November 5, 2003Date of Patent: June 29, 2010Assignee: Helperby Therapeutics LimitedInventor: Anthony Robert Milnes Coates
-
Publication number: 20100158952Abstract: The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the same and to a method of prevention and treatment of core-1 positive disorders using the same. The invention relates to microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates.Type: ApplicationFiled: November 12, 2007Publication date: June 24, 2010Inventor: Steffen Goletz
-
Publication number: 20100158941Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: ApplicationFiled: December 17, 2009Publication date: June 24, 2010Inventors: Jiri Pillich, John Balcarek
-
Patent number: 7740869Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.Type: GrantFiled: April 8, 2005Date of Patent: June 22, 2010Assignee: Absynth Biologics Ltd.Inventor: Simon J. Foster
-
Patent number: 7740870Abstract: The present invention relates to antigens, more particularly antigens of Group B Streptococcus (GBS) (S. agalactiae) which may be useful to prevent, diagnose and/or treat streptococcal infections.Type: GrantFiled: June 9, 2008Date of Patent: June 22, 2010Assignee: ID Biomedical CorporationInventors: Denis Martin, Stéphane Rioux, Bernard R. Brodeur, Josée Hamel, Martine Boyer
-
Publication number: 20100150929Abstract: The present invention relates to a streptococcal octapeptide AXYLXXLN, and preferably to the octapeptide AXYLZZLN, designated as peptide associated with rheumatic fever (PARF) that, through its interaction with human collagen, plays a crucial role in the pathogenesis of rheumatic fever. PARF therefore represents a marker for rheumatic fever associated strains and provides a target for therapies, and in particular preventive therapies.Type: ApplicationFiled: June 1, 2007Publication date: June 17, 2010Inventors: Gursharan S. Chhatwal, Patric D. Nitsche-Schmitz, Katrin Dinkla, Vanessa Barroso
-
Publication number: 20100150956Abstract: Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus and other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as a capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.Type: ApplicationFiled: February 23, 2010Publication date: June 17, 2010Inventors: JOSEPH M. PATTI, TIMOTHY J. FOSTER, MAGNUS HOOK
-
Publication number: 20100143400Abstract: The invention relates to immunostimulatory oligonucleotides and methods of using immunostimulatory oligonucleotides to induce an antigen-specific immune response. The invention further relates to a vaccine that comprises an immunostimulatory oligonucleotide and an antigen, and comprises a pharmaceutically acceptable carrier. The immunostimulatory oligonucleotides of the invention, in some embodiments, include one or more modified linkage(s).Type: ApplicationFiled: December 8, 2009Publication date: June 10, 2010Inventors: HEATHER DAVIS, RISINI WEERATNA
-
Publication number: 20100136043Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: ApplicationFiled: October 21, 2009Publication date: June 3, 2010Applicant: AUSTIN RESEARCH INSTITUTEInventor: Magdalena Plebanski
-
Publication number: 20100136050Abstract: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvants are demonstrated to enhance the immunogenicity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.Type: ApplicationFiled: October 13, 2009Publication date: June 3, 2010Applicants: University of Notre Dame Du Lac, Cook Biotech, Inc.Inventors: Mark A. Suckow, William R. Wolter, Paul J. Hall
-
Patent number: 7718182Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 or a fragment thereof, S. aureus AhpC-AhpF compositions, and uses of such polypeptides and compositions. SEQ ID NO: 1 has a full length S. aureus AhpC sequence. A derivative of SEQ ID NO: 1 containing an amino His-tag and three additional carboxyl amino acids was found to produce a protective immune response against S. aureus.Type: GrantFiled: January 17, 2006Date of Patent: May 18, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Rosemarie Kelly, Loren D. Schultz, Mark A. Miller, Mark D. Yeager, Tessie McNeely
-
Patent number: 7709008Abstract: Methods for treating or preventing infections from coagulase-negative staphylococci using proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided. Methods are also provided wherein antibodies that recognize the SdrG protein or its ligand binding A region are used to treat or prevent staphylococcal infection, and these methods can also be utilized to prevent the formation of infections on indwelling medical devices.Type: GrantFiled: April 4, 2006Date of Patent: May 4, 2010Assignees: The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A & M University SystemInventors: Timothy J. Foster, Kirk McCrea, Magnus A. O. Hook, Stacey Davis, Deirdre Ni Eidhin, Orla Hartford
-
Publication number: 20100104603Abstract: The present invention relates to Staphylococcal superantigen-like protein 5 (SSL5) or homologues or derivatives thereof for use in medicine, in particular for use in the treatment of indications involving an excessive recruitment of leukocytes, such as stroke, perfusion/ischemia, transplant rejection, rheumatoid arthritis. The invention further relates to a pharmaceutical composition comprising SSL5 and a suitable excipient. The invention also provides the use of SSL5 for the preparation of a medicament for treatment of indications involving an excessive recruitment of leukocytes to a site of tissue damage, such as stroke, reperfusion/ischemic, transplant rejection and rheumatoid arthritis.Type: ApplicationFiled: April 13, 2007Publication date: April 29, 2010Inventors: Carla J.C. De Haas, Jovanka Bestebroer, Cornelis Petrus Maria Van Kessel, Johannes Antonius Gerardus Van Strijp
-
Patent number: 7691385Abstract: Polypeptides are provided, which are useful to produce specific monoclonal or polyclonal antibodies that serve as detection means in order to characterize any staphylococcal strain carrying genes encoding resistance to streptogramin A or to streptogramin B.Type: GrantFiled: April 20, 2005Date of Patent: April 6, 2010Assignee: Institut PasteurInventors: Nevine El Solh, Jeanine Allignet
-
Patent number: 7674465Abstract: The invention provides a novel gene and protein regulating the expression of Bacillus anthracis Anthrolysin O toxin, pharmaceutical compositions and antibodies which may be utilized for human or veterinary applications or for agricultural applications, and methods of treatment using same.Type: GrantFiled: June 25, 2007Date of Patent: March 9, 2010Assignee: Philadelphia Health and Education CorporationInventors: Richard F. Rest, Daniel J. Simon, Elise M. Mosser
-
Publication number: 20100055130Abstract: The invention provides proteins from Staphylococcus aureus, including amino acid sequences and corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies, and as targets for antibiotics.Type: ApplicationFiled: October 6, 2009Publication date: March 4, 2010Applicant: Novartis AGInventors: Vega Masignani, Marirosa Mora, Maria Scarselli
-
Publication number: 20100047267Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.Type: ApplicationFiled: July 17, 2009Publication date: February 25, 2010Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
-
Patent number: 7666438Abstract: Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus and other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as ca capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.Type: GrantFiled: March 9, 2004Date of Patent: February 23, 2010Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of the College of the Holy and Undivived Trinity of Queen Elizabeth Near Dublin, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
-
Publication number: 20100021503Abstract: The present application relates to immunogenic compositions comprising Type 5 and Type 8 capsular polysaccharide or oligosaccharide from S. aureus. Methods of using and processes to make an immunogenic composition are also described.Type: ApplicationFiled: March 29, 2007Publication date: January 28, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Denoel, Jan Poolman
-
Patent number: 7648707Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: GrantFiled: February 11, 2008Date of Patent: January 19, 2010Assignee: Immunology Laboratories, Inc.Inventors: Jiri Pillich, John C. Balcarek
-
Patent number: 7648830Abstract: A method is provided for determining the presence of a target bacteria based on its resistance to a cell lysing antibiotic. Said antibiotic is used to lyse cells of non-target bacteria in a sample and hence facilitate isolation of the target prior to detection by known means.Type: GrantFiled: September 2, 2002Date of Patent: January 19, 2010Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern IrelandInventors: David James Squirrell, Rachel Louise Leslie, Kevin J Bown
-
Patent number: 7628994Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. epidermidis, methods for isolating such antigens and specific uses thereof.Type: GrantFiled: March 31, 2004Date of Patent: December 8, 2009Assignee: Intercell AGInventors: Andreas Meinke, Duc Min Bui, Eszter Nagy
-
Publication number: 20090285851Abstract: The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with ?-galactosylceramide (?GalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.Type: ApplicationFiled: November 28, 2007Publication date: November 19, 2009Applicant: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATIONInventors: Chang-Yuil Kang, Hyun-Jeong Ko, Jung-Mi Lee, Yeon-Jeong Kim
-
Patent number: 7611720Abstract: The invention relates to a live recombinant Mycobacterium bovis-BCG strain comprising a nucleic acid capable of expression, the nucleic acid encoding at least one protein or polypeptide that exhibits alanine dehydrogenase activity, glutamine synthetase activity, or serine dehydratase activity.Type: GrantFiled: April 16, 2003Date of Patent: November 3, 2009Inventors: Jun Liu, Jeffrey Chen, David Alexander
-
Patent number: 7608276Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.Type: GrantFiled: March 27, 2002Date of Patent: October 27, 2009Assignee: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Marirosa Mora, Maria Scarselli
-
Publication number: 20090263423Abstract: This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.Type: ApplicationFiled: March 25, 2009Publication date: October 22, 2009Applicant: Juvaris BioTherapeutics, Inc.Inventors: Jeffery Fairman, Marla Lay Vaughn
-
Patent number: 7605248Abstract: Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.Type: GrantFiled: September 26, 2006Date of Patent: October 20, 2009Assignees: Research Foundation of the State University of New York, Brookhaven Sciences Associates, LLCInventors: Raymond J. Dattwyler, Maria J. C. Gomes-Solecki, Benjamin J. Luft, John J. Dunn
-
Patent number: 7601358Abstract: Mycobacterium tuberculosis proteins and protein compositions that are components of a desaturase complex are provided. The Mycobacterium tuberculosis desaturase complex may include a desaturase and an oxidoreductase. The complex may include the rv3229c and rv3230c gene products of Mycobacterium tuberculosis. Vectors for expressing the desaturase and the oxidoreductase can be packaged together, including a label that indicates their use as a complex for analyzing desaturation of fatty acids. In addition, methods for screening target ligands specific for a desaturase complex are also provided.Type: GrantFiled: September 4, 2007Date of Patent: October 13, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Brian G. Fox, Yong Chang
-
Patent number: 7588920Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: January 23, 2007Date of Patent: September 15, 2009Assignee: WyethInventors: Lynn Doucette-Stamm, David Bush
-
Patent number: 7585658Abstract: The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising such polypeptides; recombinant methods to manufacture such polypeptides; and therapeutic antibodies directed to such polypeptides.Type: GrantFiled: October 24, 2005Date of Patent: September 8, 2009Assignee: Biosynexus IncorporatedInventors: Simon Foster, Philip McDowell, Kirsty Brummell, Simon Clarke
-
Publication number: 20090214537Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: ApplicationFiled: May 12, 2006Publication date: August 27, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Marco Soriani, Isabella Santi
-
Publication number: 20090202593Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: ApplicationFiled: June 16, 2008Publication date: August 13, 2009Applicant: WyethInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 7566776Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: August 6, 2007Date of Patent: July 28, 2009Assignee: WyethInventors: Lynn Doucette-Stamm, David Bush
-
Publication number: 20090136623Abstract: The present invention relates to growth-inhibitory composition against pathogenic bacteria of meat based food stuff comprising IgY, a specific immunoglobulin derived from yolk of egg. The 12 representative bacteria and other microbes deteriorating quality of process meat products that the IgY of the present invention targets include Aeromonas hydrophila, Bacilluis cereus, Campylobacter jejuni, Clostridium perfringens, 0157: H7 (Escherichia coli 0157:H7), Lactobacillus, Listeria monocytogens, Sacromyces cerevisae, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus, and Staphylococcus epidermidis. As the form of antigen, the 12 bacteria are injected to chickens separately to obtain IgY of the present invention against the 12 pathogens.Type: ApplicationFiled: March 12, 2007Publication date: May 28, 2009Inventor: Min-Seok SONG
-
Patent number: 7534857Abstract: A biologically pure RNAIII inhibiting peptide (RIP), that includes five contiguous amino acids of the sequence YX2PX1TNF, where X1 is C, W, I or a modified amino acid, and X2 is K or S is provided. The RIP further includes amino acids having a sequence that differs from the sequence YX2PX1TNF by two substitutions or deletions, where X1 is C, W, I or a modified amino acid, and X2 is K or S. This agent offers improved protection against and treatment of staphylococcal infections, and related bacteria infections, in mammals.Type: GrantFiled: May 1, 2006Date of Patent: May 19, 2009Assignee: Centegen, Inc.Inventor: Naomi Balaban
-
Publication number: 20090092639Abstract: Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed.Type: ApplicationFiled: December 17, 2008Publication date: April 9, 2009Inventors: Mark E. Cook, David L. Trott, Mingder Yang
-
Publication number: 20090017052Abstract: The present invention provides methods of identifying lethal, virulent and rapidly replicating viruses, organisms, and malignancies comprising comparing Replikin concentrations among different viruses, organisms, or malignancies. The present invention further provides isolated Replikin Peak Genes associated with increased lethality, virulence and rapid replication, for diagnostic, therapeutic and predictive purposes.Type: ApplicationFiled: January 18, 2008Publication date: January 15, 2009Inventors: Samuel Bogoch, Elenore S. Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi
-
Publication number: 20080311146Abstract: The present invention discloses an immunogenic composition comprising at least two different isolated staphylococcal polypeptides, each comprising an IgG binding domain. In a further embodiment, the invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain.Type: ApplicationFiled: December 19, 2006Publication date: December 18, 2008Applicant: Glaxosmithkline Biologicals S.A.Inventors: Cindy Castado, Cecile Anne Neyt, Jan Poolman
-
Publication number: 20080299127Abstract: The present invention relates to a pharmaceutical composition or a medicament, notably a protective Staphylococcus aureus vaccine, comprising at least one cell wall-associated Staphylococcus aureus protein or a fragment or derivative thereof causing an immune response that induces opsonophagocytic activity of human neutrophils for S. aureus. The invention further provides particular cell wall-associated Staphylococcus aureus proteins and their use.Type: ApplicationFiled: May 5, 2008Publication date: December 4, 2008Inventors: Martin Kroenke, Oleg Krut, Eva Glowalla, Bettina Tosetti
-
Patent number: 7449189Abstract: Staphylococcal and Enterrococcal glycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure.Type: GrantFiled: January 25, 2006Date of Patent: November 11, 2008Assignee: NABI BiopharmaceuticalsInventors: Ali I. Fattom, Robert B. Naso
-
Publication number: 20080226729Abstract: The present invention is directed to methods for preparing a stable powder formulation of an alum-adsorbed vaccine. The methods comprise atomizing a liquid formulation comprising an immunogen adsorbed onto an aluminum adjuvant to produce an atomized formulation, freezing the atomized formulation to produce frozen particles, and drying the frozen particles to produce dried powder particles. Pharmaceutical compositions comprising a stable powder formulation of an alum-adsorbed vaccine are also disclosed herein. The pharmaceutical compositions are stable at high temperatures and can be reconstituted in a pharmaceutically acceptable carrier to produce a reconstituted liquid vaccine that exhibits little or no particle agglomeration and retains immunogenicity. Methods of using the alum-adsorbed vaccine compositions for preventing and treating a disease in a subject, wherein the disease is associated with the particular immunogen, are further provided.Type: ApplicationFiled: September 10, 2007Publication date: September 18, 2008Applicant: Becton, Dickinson and CompanyInventors: Vincent J. Sullivan, John A. Mikszta, Jason B. Alarcon, Matthew S. Ferriter, Joanne Huang, Ajit M. D'Souza
-
Patent number: 7416862Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: July 30, 2004Date of Patent: August 26, 2008Assignee: WyethInventors: Lynn A. Doucette-Stamm, David Bush
-
Patent number: 7410647Abstract: A method for the identification of antigenic polypeptides, typically opsonic antigens, expressed by pathogenic microbes; vaccines comprising said antigens; and therapeutic antibodies directed to said antigenic polypeptides.Type: GrantFiled: August 2, 2002Date of Patent: August 12, 2008Assignees: University of Sheffield, Biosynexus IncorporatedInventors: Simon Foster, James Mond, Simon Clarke, Philip McDowell, Kristy Brummel
-
Patent number: 7407789Abstract: The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of thrombolytics and anticoagulant. Based on the trimensional structural analysis of the monomer and dimer of recombinant staphylokinases and their biochemical properties, we designed two novel bifunctional staphylokinase molecular structures. Mutant genes were constructed by PCR site-directed mutagenesis, which were then recombined with a prokaryotic vector and used to transform E. coli. Engineered strains with a high expression level were selected by screening and propagated by fermentation, followed by disruption of the cells, centrifugation to collect inclusion bodies, renaturation, and purification of RGD/KGD-SAK through a two-step method. After lyophilized, the polymerizing ability and immunogenicity of the products decreased significantly.Type: GrantFiled: January 23, 2001Date of Patent: August 5, 2008Assignee: Fudan UniversityInventors: Houyan Song, Gang Song
-
Publication number: 20080160045Abstract: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.Type: ApplicationFiled: January 3, 2008Publication date: July 3, 2008Applicant: Novartis Vaccines and Diagnostics, s.r.l.Inventors: Mario Contorni, Massimo Maffei
-
Patent number: 7393536Abstract: The present invention relates to antigens, more particularly antigens of Group B Streptococcus (GBS) (S. agalactiae) which may be useful to prevent, diagnose and/or treat streptococcal infections.Type: GrantFiled: July 5, 2002Date of Patent: July 1, 2008Assignee: ID Biomedical CorporationInventors: Denis Martin, Stéphane Rioux, Bernard R. Brodeur, Josée Hamel, Martine Boyer
-
Publication number: 20080145383Abstract: Described is a method for making a pharmaceutical preparation comprising the solubilisation of a peptide mixture, characterized in that the peptide mixture is solubilized by an aqueous solution containing at least one organic acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid and halogenated or hydroxylated forms thereof.Type: ApplicationFiled: March 11, 2005Publication date: June 19, 2008Applicant: Intercell AGInventors: Wolfgang Zauner, Constantia Kritsch, Christa Heinrich-Cseh, Agnes Berger